Hemostatic Compositions for Specialized Environments

Publication ID: 24-11857564_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Hemostatic Compositions for Specialized Environments,” Published Technical Disclosure No. 24-11857564_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857564_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,564.

Summary of the Inventive Concept

The inventive concept relates to hemostatic compositions adapted for specific, niche environments, such as high-altitude, disaster relief, extreme weather, high-security, and remote or isolated locations, ensuring effective bleeding control in these unique settings.

Background and Problem Solved

The original patent disclosed hemostatic compositions comprising an anion exchanger and a calcium salt. However, these compositions may not be optimized for specific, challenging environments. The inventive concept addresses this limitation by adapting the hemostatic compositions for use in specialized environments, where bleeding control is critical.

Detailed Description of the Inventive Concept

The inventive concept comprises hemostatic compositions that incorporate an anion exchanger and a calcium salt, tailored to function effectively in high-altitude environments, disaster relief scenarios, extreme weather conditions, high-security environments, and remote or isolated locations. For example, the composition for high-altitude environments is adapted to function at low atmospheric pressures, while the composition for high-security environments is designed to be resistant to tampering or sabotage. The inventive concept also encompasses methods and systems for inducing hemostasis in these specialized environments, including portable containers and delivery devices.

Novelty and Inventive Step

The inventive concept's novelty lies in its adaptation of hemostatic compositions for specific, niche environments, which is not addressed in the original patent. The inventive step is the recognition of the need for specialized hemostatic compositions and the development of tailored solutions for these environments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include variations in the anion exchanger and calcium salt used, as well as modifications to the composition's physical form, such as a spray or gel. Additionally, the inventive concept could be extended to other specialized environments, such as space exploration or military operations.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in industries such as emergency medical response, disaster relief, high-security operations, and remote or isolated healthcare. The adapted hemostatic compositions could be marketed as specialized products for these niche environments, offering a competitive advantage over existing hemostatic products.

Field of Art

Medical hemostatic technologies, specifically compositions for controlling bleeding using chemical interactions, requiring expertise in biochemistry, polymer chemistry, and medical device design

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degree in biomedical engineering or chemistry, familiar with hemostatic material design, understanding of ion exchange mechanisms, and experience developing medical interventions for emergency and specialized environments

Obviousness Rationale

A person skilled in the art would recognize that adapting hemostatic compositions for specialized environments represents a straightforward engineering optimization using known chemical principles from the source patent. The core hemostatic mechanism involving anion exchangers and calcium salts remains fundamentally unchanged, with variations primarily addressing contextual deployment challenges. The PTD's modifications represent predictable extensions of existing hemostatic technology targeting specific use cases.

Obvious Combinations & Variations

Source Patent Element
Anion exchanger with positively-charged DEAE groups bound to a matrix
PTD Variation
Adapting composition for high-altitude or extreme environmental conditions
Obviousness Reasoning
Modifying material properties for environmental performance is a standard engineering design choice with predictable outcomes using known chemical modification techniques
Source Patent Element
Hemostatic composition devoid of blood clotting proteins
PTD Variation
Developing composition for high-security environments with tamper-resistance
Obviousness Reasoning
Introducing additional material stability features represents a routine engineering optimization using known chemical and formulation strategies
Source Patent Element
Composition in slurry or liquid form with pharmaceutically acceptable carrier
PTD Variation
Creating portable delivery systems for disaster relief and remote locations
Obviousness Reasoning
Adapting delivery mechanisms for specific use contexts is a predictable variation using standard medical device design principles
Source Patent Element
Calcium salt component of hemostatic composition
PTD Variation
Tailoring calcium salt concentration for specific environmental performance
Obviousness Reasoning
Adjusting chemical component ratios to optimize performance in different conditions is a standard scientific approach with expected, reproducible results
Source Patent Element
Basic hemostatic composition with anion exchanger
PTD Variation
Incorporating communication technologies for remote medical information transmission
Obviousness Reasoning
Integrating communication capabilities represents a predictable technological enhancement using known medical monitoring and communication techniques
35 U.S.C. § 103 Summary: Based on US Patent 11857564's comprehensive disclosure of hemostatic compositions, the present publication demonstrates that variations targeting specialized environmental deployment represent obvious extensions of the foundational hemostatic technology, rendering subsequent claims involving similar compositional and contextual adaptations anticipated and non-patentable under standard obviousness analysis.

Original Patent Information

Patent NumberUS 11,857,564
TitleHemostatic composition comprising an anion exchanger and a calcium salt
Assignee(s)Omrix Biopharmaceuticals Ltd.